1,878 results on '"Maloney, David G"'
Search Results
2. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation
3. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
4. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
5. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
6. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
7. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
8. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
9. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
10. qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue
11. Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.
12. Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
13. Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma
14. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
15. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
16. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
17. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
18. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
19. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
20. Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.
21. PD‐L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B‐cell lymphoma microenvironment impact CD19 CAR‐T cell immunotherapy efficacy.
22. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
23. Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels
24. Comparative Study Evaluating Hospitalizations and Critical Care Stays Among Patients with R/R Large B-Cell Lymphoma (LBCL) Treated with CAR T Cell Therapies Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) in the Inpatient (IP) and Outpatient (OP) Setting Using United States (US) Claims Data
25. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis
26. Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy
27. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
28. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
29. Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy
30. Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel
31. Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity
32. T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case Series
33. Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) With R/R CLL/SLL: 24-Mo Median Follow-up of TRANSCEND CLL 004
34. Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic
35. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma
36. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
37. Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies
38. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
39. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
40. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy
41. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
42. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
43. Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting
44. Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up
45. Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel
46. 2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study
47. Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy
48. Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma
49. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
50. Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.